Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia
The DOI matches its Crossref record.
Abstract
Sir, Over time Neisseria gonorrhoeae has developed resistance to a wide range of antimicrobials, including cephalosporins, limiting treatment options.1 We report a case of persistent pharyngeal N. gonorrhoeae despite administration of 500 mg of ceftriaxone by intramuscular injection, a dose exceeding that currently recommended in some countries for gonorrhoea. We obtained informed consent from the index patient to publish this report. A homosexual man presented to a Melbourne clinic in 2010 (day 0) complaining of anal discomfort. His regular male partner had been diagnosed with gonorrhoea and therefore he was given 500 mg of ceftriaxone by intramuscular injection. Both rectal and pharyngeal swabs grew N. gonorrhoeae. On day 22, a repeat pharyngeal swab grew N. gonorrhoeae. He returned on day 34. A third pharyngeal swab was taken before he was given 2 g of azithromycin. N. gonorrhoeae was again isolated. He reported that he had not had any sexual contact since his first visit. Pharyngeal and rectal swabs taken on day 41 were negative for N. gonorrhoeae on culture and by Abbott m2000 real-time PCR testing. The patient's regular male partner presented to a general practitioner with conjunctival and urethral gonorrhoea confirmed by nucleic acid amplification testing (NAAT) and was treated with cefalexin, doxycycline and amoxicillin. Pharyngeal and rectal swabs for culture and urine NAAT for N. gonorrhoeae taken 2 months later were negative. He reported that the last time he had sex was with his regular partner and that this was prior to day 0 above. Isolates were identified as N. gonorrhoeae based on Gram's stain, oxidase, carbohydrate utilization reactions and the MicroTrak®N. gonorrhoeae Culture Confirmation Test (Trinity Biotech) and confirmed by porA pseudogene and opa gene PCR assays. MICs were determined by agar plate dilution using the method of the Australian Gonococcal Surveillance Programme (AGSP)2 and Etests (AB bioMérieux). For all four isolates and all antimicrobials, the MIC values fell within one dilution of each other. The MIC values obtained and the AGSP interpretive categories were as follows: ceftriaxone, 0.03–0.06 mg/L (decreased susceptibility); ciprofloxacin, 8–16 mg/L (resistant); penicillin, 1–2 mg/L (less susceptible); spectinomycin, ≤64 mg/L (susceptible); and azithromycin, 0.25–0.5 mg/L (susceptible). The rectal and pharyngeal isolates from day 0 and the pharyngeal isolates from days 22 and 34 were examined by PFGE. Indistinguishable PFGE patterns were obtained for all four isolates. N. gonorrhoeae multi-antigen sequence typing (NG-MAST) of isolates from day 0 and day 22 identified them as sequence type (ST) 1407. The isolate from day 34 was ST4950. ST4950 contains a 3 base duplication in the por allele compared with ST1407, most likely due to a DNA replication error of the original ST1407 isolate in situ. Partial sequencing of the penA and porB genes revealed that all four isolates contained a mosaic penicillin-binding protein 2 type XXXIV and porB1b alterations G101K/A102N. N. gonorrhoeae was isolated from pharyngeal cultures taken 22 and 34 days after 500 mg of ceftriaxone. The day 22 isolate was indistinguishable from the day 0 isolate when compared by PFGE and NG-MAST. The day 34 isolate was also indistinguishable by PFGE, but was of a different, yet closely related, NG-MAST type. These findings, together with the reported absence of sexual activity, suggests the failure of 500 mg of ceftriaxone to eradicate pharyngeal N. gonorrhoeae. While re-infection could explain the results, the index patient and partner reported sexual abstinence following treatment. All four isolates showed decreased susceptibility to ceftriaxone with an MIC value of 0.03–0.06 mg/L. According to the AGSP the ceftriaxone MIC range 0.06–0.125 mg/L corresponds to decreased susceptibility and this is the highest MIC category reported for ceftriaxone. In 2010, in Australia, 4.8% of isolates tested had an MIC of ceftriaxone in this range.3 Higher ceftriaxone MIC values (0.125–0.25 mg/L) have been reported elsewhere,4 but not in Australia. These higher MIC values could in part be attributed to the use of EUCAST criteria elsewhere, based on a different MIC methodology. The isolates were NG-MAST type ST1407 (or the closely related ST4950), which is a clone of N. gonorrhoeae with decreased susceptibility to extended-spectrum cephalosporins that has disseminated globally4 and was associated with genital gonorrhoea treatment failure using 400 mg of cefixime.5 The isolates also harboured a mosaic penicillin-binding protein 2 type XXXIV and porB1b alterations G101K/A102N, recognized contributors to cephalosporin resistance.4 While the high ceftriaxone MICs for the above isolates would have contributed to pharyngeal treatment failure for the index patient, it should be noted that isolates with such MICs are increasingly being found in pharyngeal samples, but with only one other report of treatment failure at the 500 mg d
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually transmitted diseases treatment guidelines (2015)
Workowski, K., & BOLAN, G. A. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.24.51-56 · Cited by 2,698
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future
Unemo, M., & Shafer, W. M. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00010-14 · Cited by 1,151
Wi, T., Lahra, M. M., Ndowa, F., Bala, M., Dillon, J.-A. R., Ramon-Pardo, P., Eremin, S. R., Bolan, G., & Unemo, M. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002344 · Cited by 600
Self-citation
Metadata
- Authors
- Y. Chen, M., Stevens, K., Tideman, R., Zaia, A., Tomita, T., Fairley, C. K., Lahra, M., Whiley, D., & Hogg, G.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02-06
- Volume
- 68
- Issue
- 6
- Pages
- 1445-1447
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2096919304
- Cited by
- 87
- References
- 0
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. https://app.cochat.ai/papers/10.1093/jac/dkt017
- The paper
- Y. Chen, M., Stevens, K., Tideman, R., Zaia, A., Tomita, T., Fairley, C. K., Lahra, M., Whiley, D., & Hogg, G. (2013). Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkt017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.